Hunan Fangsheng Pharm Co Ltd
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infe… Read more
Hunan Fangsheng Pharm Co Ltd (603998) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.28 Billion CNY
Based on the latest financial reports, Hunan Fangsheng Pharm Co Ltd (603998) has total liabilities worth CN¥1.28 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hunan Fangsheng Pharm Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Hunan Fangsheng Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hunan Fangsheng Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hunan Fangsheng Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bouvet
OL:BOUV
|
Norway | Nkr1.30 Billion |
|
Civista Bancshares Inc
NASDAQ:CIVB
|
USA | $3.79 Billion |
|
Red River Bancshares Inc
NASDAQ:RRBI
|
USA | $2.99 Billion |
|
Citra Marga Nusaphala Persada
JK:CMNP
|
Indonesia | Rp8.89 Trillion |
|
Huayi Compressor Co Ltd
SHE:000404
|
China | CN¥9.52 Billion |
|
Farmers National Banc Corp
NASDAQ:FMNB
|
USA | $4.76 Billion |
|
Western Copper and Gold Corp
NYSE MKT:WRN
|
USA | $5.48 Million |
|
LANXESS Aktiengesellschaft
PINK:LNXSY
|
USA | $4.28 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Hunan Fangsheng Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Fangsheng Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Fangsheng Pharm Co Ltd (2011–2024)
The table below shows the annual total liabilities of Hunan Fangsheng Pharm Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.53 Billion | +2.64% |
| 2023-12-31 | CN¥1.49 Billion | +5.52% |
| 2022-12-31 | CN¥1.41 Billion | +0.95% |
| 2021-12-31 | CN¥1.40 Billion | +43.37% |
| 2020-12-31 | CN¥977.05 Million | +23.29% |
| 2019-12-31 | CN¥792.51 Million | +49.58% |
| 2018-12-31 | CN¥529.81 Million | +57.97% |
| 2017-12-31 | CN¥335.39 Million | +15.13% |
| 2016-12-31 | CN¥291.31 Million | +115.88% |
| 2015-12-31 | CN¥134.94 Million | +56.03% |
| 2014-12-31 | CN¥86.48 Million | +8.79% |
| 2013-12-31 | CN¥79.50 Million | +39.51% |
| 2012-12-31 | CN¥56.98 Million | -17.28% |
| 2011-12-31 | CN¥68.89 Million | -- |